2014
Poster #T200 SUBGROUP ANALYSIS IN A RANDOMIZED CLINICAL TRIAL OF LONG-ACTING INJECTABLE RISPERIDONE AND ORAL ANTIPSYCHOTICS IN UNSTABLE CHRONIC SCHIZOPHRENIA
Rosenheck R, Leatherman S, Krystal J, Liang M. Poster #T200 SUBGROUP ANALYSIS IN A RANDOMIZED CLINICAL TRIAL OF LONG-ACTING INJECTABLE RISPERIDONE AND ORAL ANTIPSYCHOTICS IN UNSTABLE CHRONIC SCHIZOPHRENIA. Schizophrenia Research 2014, 153: s360. DOI: 10.1016/s0920-9964(14)71016-3.Peer-Reviewed Original ResearchDifferences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2014, 202: 13-17. PMID: 24375206, DOI: 10.1097/nmd.0000000000000069.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntipsychotic AgentsChronic DiseaseDrug Administration ScheduleFemaleHospitalizationHumansInjections, IntramuscularMaleMiddle AgedProportional Hazards ModelsPsychotic DisordersQuality of LifeRisk AssessmentRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexSubstance-Related DisordersTreatment OutcomeConceptsQuality of lifeOral antipsychoticsOral treatmentInjectable risperidoneCox regressionTreatment effectsLong-Acting Injectable RisperidoneBody mass indexPsychiatric service useSubstance abuse outcomesSubstance use outcomesLAI risperidonePrimary endpointStudy entryWhite patientsClinical outcomesMass indexUnstable patientsMedication compliancePsychiatric rehospitalizationChronic schizophreniaClinical trialsClinical subgroupsPsychiatric hospitalizationPsychiatric symptoms
2012
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG, Scott JY, Krystal JH, Rosenheck RA. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal Of Clinical Psychiatry 2012, 73: 696-702. PMID: 22697193, DOI: 10.4088/jcp.11m07070.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsComparative Effectiveness ResearchCost-Benefit AnalysisDelayed-Action PreparationsDouble-Blind MethodDrug CostsFemaleHealth Care CostsHospitalizationHumansInjectionsKaplan-Meier EstimateMaleMiddle AgedModels, EconometricPsychotic DisordersRisperidoneSchizophreniaUnited StatesVeteransConceptsTotal health care costsHealth care costsLAI risperidoneMedication costsControl groupCare costsVeterans Health Administration patientsHealth care utilizationHealth Related QualityStructured Clinical InterviewUS Medicaid programCase report formsMultisite clinical trialQuality of WellExperimental groupOral antipsychoticsAdverse eventsCare utilizationInjectable risperidoneOutpatient costsHospitalization costsClinical trialsRelated qualityLAI groupPhysician's choice
2011
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH. Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. New England Journal Of Medicine 2011, 364: 842-851. PMID: 21366475, DOI: 10.1056/nejmoa1005987.Peer-Reviewed Original ResearchConceptsInjectable risperidoneOral antipsychoticsQuality of lifeSchizoaffective disorderPsychiatrist's choiceSecond-generation antipsychotic agentsMore adverse eventsMore extrapyramidal symptomsPrimary end pointNeurologic side effectsExtrapyramidal adverse effectsRate of hospitalizationVeterans Affairs systemSocial Performance ScaleAdverse eventsExtrapyramidal symptomsOral treatmentAntipsychotic agentsUnstable diseasePsychiatric symptomsHigh riskHospitalizationSide effectsPatientsPsychiatric hospital